BR112013031943A2 - "proteínas e anticorpos contra g-csfr, composição que os compreendem e uso dos mesmos". - Google Patents
"proteínas e anticorpos contra g-csfr, composição que os compreendem e uso dos mesmos".Info
- Publication number
- BR112013031943A2 BR112013031943A2 BR112013031943A BR112013031943A BR112013031943A2 BR 112013031943 A2 BR112013031943 A2 BR 112013031943A2 BR 112013031943 A BR112013031943 A BR 112013031943A BR 112013031943 A BR112013031943 A BR 112013031943A BR 112013031943 A2 BR112013031943 A2 BR 112013031943A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- composition
- csfr
- proteins
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
abstract the present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor. tradução do resumo resumo patente de invenção: "anticorpos contra g-csfr e usos dos mesmos". a presente divulgação fornece proteínas compreendendo domínios de ligação a antígeno de anticorpos que se ligam a receptor de fator de estimulação de colônia de granulócito humano.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161496351P | 2011-06-13 | 2011-06-13 | |
US61/496,351 | 2011-06-13 | ||
PCT/AU2012/000675 WO2012171057A1 (en) | 2011-06-13 | 2012-06-13 | Antibodies against g-csfr and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013031943A2 true BR112013031943A2 (pt) | 2016-11-22 |
BR112013031943B1 BR112013031943B1 (pt) | 2021-10-13 |
Family
ID=47353852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013031943-7A BR112013031943B1 (pt) | 2011-06-13 | 2012-06-13 | Composição que compreende proteínas e anticorpos contra g-csfr |
Country Status (15)
Country | Link |
---|---|
US (5) | US9193793B2 (pt) |
EP (1) | EP2718326B1 (pt) |
JP (1) | JP6187777B2 (pt) |
KR (1) | KR101822702B1 (pt) |
CN (1) | CN103649123B (pt) |
AU (1) | AU2012269720B2 (pt) |
BR (1) | BR112013031943B1 (pt) |
CA (1) | CA2838246C (pt) |
DK (1) | DK2718326T3 (pt) |
ES (1) | ES2828482T3 (pt) |
IL (1) | IL229468B (pt) |
MX (1) | MX343580B (pt) |
RU (1) | RU2605595C2 (pt) |
SG (1) | SG195043A1 (pt) |
WO (1) | WO2012171057A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2828482T3 (es) | 2011-06-13 | 2021-05-26 | Csl Ltd | Anticuerpos contra el g-csfr y su uso |
WO2016164637A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
CA3077215A1 (en) * | 2017-10-11 | 2019-04-18 | Elanco Us Inc. | Porcine g-csf variants and their uses |
KR102684627B1 (ko) | 2017-11-29 | 2024-07-15 | 씨에스엘 리미티드 | 허혈-재관류 손상을 치료 또는 예방하는 방법 |
US20210009677A1 (en) * | 2018-03-23 | 2021-01-14 | Csl Limited | Method of treating asthma |
SI3618928T1 (sl) | 2018-07-13 | 2023-04-28 | Alector Llc | Protitelesa proti sortilinu in postopki za uporabo le-teh |
WO2020113270A1 (en) * | 2018-12-04 | 2020-06-11 | CSL Innovation Pty Ltd | Method of treating neutrophilic conditions |
EP3983448A4 (en) * | 2019-06-12 | 2023-11-22 | CSL Innovation Pty Ltd | SOLUBLE COMPLEMENT RECEPTOR TYPE 1 VARIANT CONJUGATES AND RELATED USES |
CA3151471A1 (en) * | 2019-10-08 | 2021-04-15 | Gesa VOLKERS | Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same |
CA3175686A1 (en) * | 2020-06-04 | 2021-12-09 | Adriana BAZ MORELLI | Method of treating or preventing acute respiratory distress syndrome |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE66494B1 (en) * | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
EP1493825A3 (en) | 1990-06-11 | 2005-02-09 | Gilead Sciences, Inc. | Method for producing nucleic acid ligands |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
EP0569141A3 (en) | 1992-04-14 | 1994-10-26 | Hybritech Inc | Method for inhibiting the growth of multidrug-resistant tumors by antibodies. |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
EP1550729B1 (en) | 1992-09-25 | 2009-05-27 | Avipep Pty Limited | Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain |
AUPM375194A0 (en) | 1994-02-08 | 1994-03-03 | Ludwig Institute For Cancer Research | Cytokine receptor interactive molecules |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
JP4187413B2 (ja) | 1998-03-20 | 2008-11-26 | コモンウェルス サイエンティフィック アンドインダストリアル リサーチ オーガナイゼーション | 遺伝子発現の制御 |
PT1068311E (pt) | 1998-04-08 | 2011-07-20 | Commw Scient Ind Res Org | Processos e meios de obter fenótipos modificados |
WO1999057134A1 (en) | 1998-05-06 | 1999-11-11 | Genentech, Inc. | Protein purification by ion exchange chromatography |
EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
JP2000319298A (ja) * | 1999-03-04 | 2000-11-21 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 蛋白質複合体の結晶、構造座標、及び構造座標の使用 |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ATE489395T1 (de) | 2000-12-12 | 2010-12-15 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
AUPR544401A0 (en) | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
JP2006526414A (ja) | 2003-06-02 | 2006-11-24 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 脱免疫化抗cd3抗体 |
US7993650B2 (en) | 2003-07-04 | 2011-08-09 | Affibody Ab | Polypeptides having binding affinity for HER2 |
WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
AU2004296376B2 (en) | 2003-12-05 | 2010-03-04 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
US7977071B2 (en) | 2004-06-02 | 2011-07-12 | Adalta Pty Ltd. | Binding moieties based on shark ignar domains |
CA2580981C (en) | 2004-09-22 | 2013-10-22 | Kirin Beer Kabushiki Kaisha | Stabilized human igg4 antibodies |
US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
EP2267030A1 (en) | 2005-08-25 | 2010-12-29 | Repair Technologies, Inc. | Devices, compositions and methods for the protection and repair of cells and tissues |
US7871979B2 (en) * | 2006-07-06 | 2011-01-18 | Merck Serono Sa | CSF3R polypeptides and uses thereof |
PL2056858T3 (pl) * | 2006-08-11 | 2015-01-30 | Csl Ltd | Leczenie stanów chorobowych płuc |
US20080199426A1 (en) | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
CL2008002782A1 (es) | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
KR20110104032A (ko) | 2008-12-19 | 2011-09-21 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이의 용도 |
BRPI1006998A2 (pt) | 2009-01-23 | 2015-08-25 | Biogen Idec Inc | Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso |
JP5785550B2 (ja) * | 2009-09-15 | 2015-09-30 | シーエスエル、リミテッド | 神経疾患の処置方法 |
US8968731B2 (en) * | 2009-10-09 | 2015-03-03 | Csl Limited | Treatment of uveitis |
CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
CN104610454A (zh) | 2010-02-16 | 2015-05-13 | 米迪缪尼有限公司 | Hsa相关组合物及使用方法 |
EP2367000A1 (en) | 2010-03-04 | 2011-09-21 | Charité Universitätsmedizin Berlin | High throughput analysis of T-cell receptor repertoires |
EP2553098B1 (en) | 2010-04-02 | 2017-10-11 | CuRNA, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
CA2815237C (en) | 2010-10-27 | 2018-10-09 | Celldex Therapeutics, Inc. | Method of improving transplant function using soluble complement receptor type i (scr1) |
JP2014510518A (ja) | 2011-02-15 | 2014-05-01 | メディミューン,エルエルシー | Hsa関連組成物および使用方法 |
ES2828482T3 (es) | 2011-06-13 | 2021-05-26 | Csl Ltd | Anticuerpos contra el g-csfr y su uso |
EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
US9050305B2 (en) | 2012-03-29 | 2015-06-09 | Chs Pharma, Inc. | Treatment for ischemic stroke |
US20140128326A1 (en) | 2012-11-08 | 2014-05-08 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
JP6306700B2 (ja) | 2013-11-01 | 2018-04-04 | ユニバーシティ オブ オスロUniversity of Oslo | アルブミン改変体及びその使用 |
KR20160124165A (ko) | 2014-02-21 | 2016-10-26 | 제넨테크, 인크. | 항-il-13/il-17 이중특이적 항체 및 그의 용도 |
KR102560025B1 (ko) | 2014-11-17 | 2023-07-26 | 씨에스엘 리미티드 | 뇌졸중의 치료 또는 예방 방법 |
US20190119369A1 (en) | 2016-04-21 | 2019-04-25 | Csl Limited | Method of treating or preventing liver conditions |
KR102684627B1 (ko) | 2017-11-29 | 2024-07-15 | 씨에스엘 리미티드 | 허혈-재관류 손상을 치료 또는 예방하는 방법 |
KR20190073917A (ko) | 2017-12-19 | 2019-06-27 | 포항공과대학교 산학협력단 | 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물 |
US20210009677A1 (en) | 2018-03-23 | 2021-01-14 | Csl Limited | Method of treating asthma |
MA52570A (fr) | 2018-05-10 | 2021-03-17 | Regeneron Pharma | Formulations contenant des protéines de fusion du récepteur vegf à haute concentration |
MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
WO2020113270A1 (en) | 2018-12-04 | 2020-06-11 | CSL Innovation Pty Ltd | Method of treating neutrophilic conditions |
EP3983448A4 (en) | 2019-06-12 | 2023-11-22 | CSL Innovation Pty Ltd | SOLUBLE COMPLEMENT RECEPTOR TYPE 1 VARIANT CONJUGATES AND RELATED USES |
-
2012
- 2012-06-13 ES ES12800867T patent/ES2828482T3/es active Active
- 2012-06-13 JP JP2014515000A patent/JP6187777B2/ja active Active
- 2012-06-13 DK DK12800867.9T patent/DK2718326T3/da active
- 2012-06-13 SG SG2013085493A patent/SG195043A1/en unknown
- 2012-06-13 BR BR112013031943-7A patent/BR112013031943B1/pt active IP Right Grant
- 2012-06-13 CN CN201280034469.6A patent/CN103649123B/zh active Active
- 2012-06-13 KR KR1020147000742A patent/KR101822702B1/ko active IP Right Grant
- 2012-06-13 AU AU2012269720A patent/AU2012269720B2/en active Active
- 2012-06-13 WO PCT/AU2012/000675 patent/WO2012171057A1/en active Application Filing
- 2012-06-13 EP EP12800867.9A patent/EP2718326B1/en active Active
- 2012-06-13 MX MX2013014711A patent/MX343580B/es active IP Right Grant
- 2012-06-13 RU RU2014100642/10A patent/RU2605595C2/ru active
- 2012-06-13 CA CA2838246A patent/CA2838246C/en active Active
- 2012-06-13 US US13/495,539 patent/US9193793B2/en active Active
-
2013
- 2013-11-17 IL IL229468A patent/IL229468B/en active IP Right Grant
-
2015
- 2015-10-19 US US14/886,176 patent/US20160031998A1/en not_active Abandoned
-
2017
- 2017-04-18 US US15/490,318 patent/US20170226214A1/en not_active Abandoned
-
2018
- 2018-08-24 US US16/111,323 patent/US20190055313A1/en not_active Abandoned
-
2020
- 2020-07-09 US US16/924,282 patent/US12071484B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2828482T3 (es) | 2021-05-26 |
US20190055313A1 (en) | 2019-02-21 |
NZ617725A (en) | 2015-02-27 |
BR112013031943B1 (pt) | 2021-10-13 |
SG195043A1 (en) | 2013-12-30 |
US20160031998A1 (en) | 2016-02-04 |
AU2012269720A1 (en) | 2013-03-21 |
EP2718326A4 (en) | 2015-07-08 |
WO2012171057A1 (en) | 2012-12-20 |
US20120321630A1 (en) | 2012-12-20 |
CA2838246C (en) | 2018-07-10 |
JP2014519517A (ja) | 2014-08-14 |
AU2012269720B2 (en) | 2015-01-22 |
IL229468B (en) | 2021-05-31 |
US9193793B2 (en) | 2015-11-24 |
EP2718326B1 (en) | 2020-08-19 |
KR101822702B1 (ko) | 2018-01-26 |
CN103649123B (zh) | 2017-05-24 |
MX343580B (es) | 2016-11-10 |
RU2605595C2 (ru) | 2016-12-20 |
IL229468A0 (en) | 2014-01-30 |
US12071484B2 (en) | 2024-08-27 |
CA2838246A1 (en) | 2012-12-20 |
US20210009701A1 (en) | 2021-01-14 |
EP2718326A1 (en) | 2014-04-16 |
MX2013014711A (es) | 2014-09-01 |
DK2718326T3 (da) | 2020-10-26 |
CN103649123A (zh) | 2014-03-19 |
KR20140041717A (ko) | 2014-04-04 |
RU2014100642A (ru) | 2015-07-20 |
US20170226214A1 (en) | 2017-08-10 |
JP6187777B2 (ja) | 2017-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013031943A2 (pt) | "proteínas e anticorpos contra g-csfr, composição que os compreendem e uso dos mesmos". | |
CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
CY1120637T1 (el) | Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40 | |
EA201400579A1 (ru) | Антитела к il-36r | |
CL2015001472A1 (es) | Composiciones y métodos para anticuerpos dirigidos epo. | |
BR112014007426A2 (pt) | anticorpos contra tl 1a e seus usos | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
WO2018226578A8 (en) | Nectin-4 binding proteins and methods of use thereof | |
BR112014007382A2 (pt) | anticorpos anti-erbb3 e seus usos | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
ECSP11011115A (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t | |
MA43055A (fr) | Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation | |
EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
CL2011000308A1 (es) | Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende; metodo de preparacion; y su uso para estimular la respuesta inmune. | |
CL2013001138A1 (es) | Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición. | |
NZ626610A (en) | Antibodies that bind csf1r | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
EA201300256A1 (ru) | Антитела к рецептору эпидермального фактора роста-3 (her3) | |
EA201291180A1 (ru) | Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
MY165038A (en) | Humanized antibodies that recognize alpha-synuclein | |
BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
EA201390847A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
EA201370081A1 (ru) | Антитела к cd48 и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2012, OBSERVADAS AS CONDICOES LEGAIS. |